NCT00830869 - A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies | Biotech Hunter

Enrollment

116

Participants

Timeline

Start Date

March 2, 2009

Primary Completion Date

April 20, 2012

Study Completion Date

April 20, 2012

Conditions

Advanced Non-hematologic Malignancies

Interventions

DRUG

IXAZOMIB

"All participants will receive IXAZOMIB IV injection on Days 1, 4, 8, and 11 of each treatment cycle followed by a rest period of 10 days.~The first stage of the study will be initiated at a starting dose of 0.125 mg/m\^2. Subsequent doses will increase until a maximum tolerated dose (MTD) is established."

Trial Locations (7)

27710

Duke University, Durham

30322

Emory University, Atlanta

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

37203

Sarah Cannon Research Institute, Nashville

48109

University of Michigan, Ann Arbor

98109

University of Washington- Seattle Cancer Care, Seattle

M5G 2M9

Princess Margaret Hospital, Toronto